Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
877.79
-31.53 (-3.47%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
99
100
Next >
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
July 25, 2024
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via
InvestorPlace
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
July 25, 2024
Investors have strong opinions on Tesla but not on LVMH or Eli Lilly, Musk agrees on Twitter. Tesla's controversial CEO and recent financial struggles may explain heightened interest.
Via
Benzinga
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
July 24, 2024
Via
Benzinga
3 Fabulous Growth Stocks to Buy and Hold Forever
July 24, 2024
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available.
Via
InvestorPlace
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.
Via
Benzinga
Market Whales and Their Recent Bets on LLY Options
July 23, 2024
Via
Benzinga
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
July 24, 2024
Their yields may seem low, but these stocks have been growing their dividend payments at a fast pace.
Via
The Motley Fool
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
July 24, 2024
Could today's momentum continue?
Via
The Motley Fool
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.
Via
The Motley Fool
Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
July 22, 2024
These stocks to buy before earnings are likely to jump higher after the companies behind them report their Q2 financial results.
Via
InvestorPlace
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
July 22, 2024
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All.
Via
Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
July 22, 2024
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.
Via
Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...
Via
Benzinga
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
July 22, 2024
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.
Via
The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Via
The Motley Fool
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
July 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Via
The Motley Fool
SPDR ETF Report For Friday, July 19
July 20, 2024
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, July 19.
Via
Talk Markets
Topics
ETFs
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
July 19, 2024
Skyrocketing demand for GLP-1 medications for weight loss is causing shortages, impacting type 2 diabetics. While some insurers are limiting off-label use, government agencies have yet to prioritize...
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
July 19, 2024
Eli Lilly's Tirzepatide approved by China's NMPA for long-term weight management, targeting adults with specific BMI criteria.
Via
Benzinga
Is Viking Therapeutics a Millionaire-Maker?
July 19, 2024
This biotech stock fits the profile of a potentially big winner to a T.
Via
The Motley Fool
Here's How Saving Just $10 Per Day for 30 Years Can Create a $1 Million Portfolio
July 19, 2024
If you can save money, finding a good investment to put that cash into won't be hard.
Via
The Motley Fool
Nvidia Recently Completed a 10-for-1 Stock Split: Here Are the 3 Likeliest Candidates to Become Wall Street's Next Stock-Split Stocks
July 19, 2024
Roughly a dozen amazing companies have announced a stock split in 2024. Three high-flying stocks look like logical candidates to join this exclusive club.
Via
The Motley Fool
Palantir, Netflix, Domino's Pizza, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
July 18, 2024
The Dow Jones Industrial Average dropping nearly 1.3% to 40,665.03 on Thursday, the S&P 500 and Nasdaq declined as well.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
July 18, 2024
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth.
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Eli Lilly And Company Shares Thursday?
July 18, 2024
Eli Lilly and Company stock is moving lower on Thursday on possible continued weakness after recent weight loss data from Roche.
Via
Benzinga
Teva's Migraine Treatment Found Effective For Children As Young As 6
July 18, 2024
Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in children aged 6-17. The trial's primary endpoint was met with safety data aligning...
Via
Benzinga
3 High-Flying Stocks That Show No Signs of Slowing Down
July 18, 2024
Eli Lilly, Wingstop and Apple are three high-flying stocks to buy, poised for continued growth despite witnessing solid price increases.
Via
InvestorPlace
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.